Phosphate Meeting Cholesterol\textemdash Consequences for Cardiovascular Disease in Chronic Kidney Disease?
Cardiovascular disease is highly prevalent in patients with chronic kidney disease. Hyperphosphatemia is associated with subclinical atheromatosis in chronic kidney disease. Phosphate-induced endothelial dysfunction and vascular calcification are thought to be key inducers of atherosclerosis in this...
Saved in:
| Published in | Kidney international Vol. 99; no. 6; pp. 1264 - 1267 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Nature Publishing Group
2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | Cardiovascular disease is highly prevalent in patients with chronic kidney disease. Hyperphosphatemia is associated with subclinical atheromatosis in chronic kidney disease. Phosphate-induced endothelial dysfunction and vascular calcification are thought to be key inducers of atherosclerosis in this condition. Zhou et al. now demonstrate that phosphate promotes de novo cholesterol synthesis in vascular smooth muscle and macrophages through increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activation. This observation may change current concepts of atherosclerosis development and management in chronic kidney disease. \textcopyright 2021 International Society of Nephrology |
|---|---|
| ISSN: | 0085-2538 1523-1755 |
| DOI: | 10.1016/j.kint.2021.02.022 |